Norton Rose Fulbright Shuffles Life Sciences Leadership Amid Rising Litigation Risks
Event summary
- Mary Young appointed Global Co-Head of Life Sciences and Healthcare at Norton Rose Fulbright, replacing Jonathan Skidmore and co-leading with Randy Sutton.
- Young brings expertise in complex product liability and mass tort litigation, with a focus on Fortune 500 companies in the life sciences and medical devices sectors.
- Norton Rose Fulbright's global life sciences and healthcare team comprises over 400 lawyers advising on regulatory, transactional, and litigation matters.
- The firm's Annual Litigation Trends Survey found nearly a third of healthcare industry respondents saw increased class action exposure last year.
- Young will continue as Minneapolis office Partner-in-Charge while taking on the new global role.
The big picture
Norton Rose Fulbright's leadership shuffle comes at a time when healthcare and life sciences companies are grappling with heightened litigation risks and regulatory pressures. The appointment of Mary Young, with her extensive litigation experience, underscores the firm's strategic focus on navigating these challenges. With over 400 lawyers in the global life sciences and healthcare team, the firm is positioning itself to support clients through an evolving legal landscape.
What we're watching
- Litigation Exposure
- How Norton Rose Fulbright's expanded leadership will address rising class action and regulatory litigation risks in the healthcare sector.
- Global Strategy
- Whether the co-leadership model can enhance collaboration across key markets and deliver innovative solutions to clients worldwide.
- Regulatory Pressure
- The pace at which healthcare and life sciences companies will face increased regulatory scrutiny and policy uncertainty.
Related topics